Alnylam Pharmaceuticals (ALNY) vs Incyte (INCY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Incyte (INCY) has outperformed Alnylam Pharmaceuticals (ALNY) over the past year, gaining 33.1% versus a loss of 49.1%. Over five years, INCY leads with a +72.0% price change compared with +11.6% for ALNY. Alnylam Pharmaceuticals is the larger company by market cap ($31.13 billion vs $22.86 billion), about 1.4 times the size.
On valuation, Incyte trades at a lower forward P/E (12.9x vs 18.7x for Alnylam Pharmaceuticals). Incyte converts more of its revenue into profit, with a net margin of 25.0% versus 8.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALNY | INCY |
|---|---|---|
| Share price | $232.68 | $112.79 |
| Market cap | $31.13B | $22.86B |
| 1-day change | +3.63% | +0.04% |
| YTD return | -41.49% | +14.19% |
| 1-year return | -49.08% | +33.09% |
| 5-year return | +11.57% | +72.04% |
| P/E ratio (TTM) | 39.24 | 14.37 |
| Forward P/E | 18.73 | 12.89 |
| EPS (TTM) | $5.93 | $7.85 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $3.71B | $5.14B |
| Revenue growth (YoY) | +65.19% | +21.22% |
| Net income (latest FY) | $313.75M | $1.29B |
| Gross margin | 81.77% | 92.76% |
| Operating margin | 13.51% | 29.46% |
| Net margin | 8.45% | 25.03% |
| 52-week high | $495.55 | $132.60 |
| 52-week low | $197.81 | $82.82 |
| Distance from 52-week high | -53.05% | -14.94% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +59.50% | +14.49% |
| Average volume | 1.78M | 1.63M |
| Shares outstanding | 133.81M | 202.70M |
| Employees | 2,500 | 2,844 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Commercial Physical & Biological Resarch |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INCY has outperformed ALNY by 82.2 percentage points over the past year.
- Alnylam Pharmaceuticals trades at a higher earnings multiple (39.2x vs 14.4x trailing P/E).
- Incyte is more profitable, keeping 25.0 cents of every revenue dollar as net income versus 8.4 cents for Alnylam Pharmaceuticals.
- Alnylam Pharmaceuticals grew revenue faster in its latest fiscal year (+65.19% vs +21.22%).
About Alnylam Pharmaceuticals
ALNY stock →Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 2,500 employees
About Incyte
INCY stock →Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 2,844 employees
ALNY vs INCY FAQ
Which is bigger, Alnylam Pharmaceuticals or Incyte?
Alnylam Pharmaceuticals (ALNY) is larger, with a market capitalization of $31.13B compared with $22.86B for Incyte (INCY).
Which stock has performed better over the past year, ALNY or INCY?
INCY returned +33.09% over the past 12 months, compared with -49.08% for ALNY (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ALNY or INCY?
INCY has the lower trailing P/E at 14.4, versus 39.2 for ALNY. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Alnylam Pharmaceuticals and Incyte in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Alnylam Pharmaceuticals and Biotechnology: Commercial Physical & Biological Resarch for Incyte.